Tecfidera (BG-12) (Multiple Sclerosis) (Wave 4) | LaunchTrends | US | 2014
LaunchTrends: Tecfidera (US) is a four-wave syndicated report series that specifically tracks the introduction of Tecfidera, the third-to-market oral disease-modifying therapy (DMT), based on primary research data collected at one month, three months, six months and one year post-commercial availability of Tecfidera. Along with awareness and sources of familiarity, the reports assess US neurologists’ trial, adoption and usage of Tecfidera, including anticipated future trends. The reports also provide information on product perceptions, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Biogen Idec’s promotional efforts and benchmarking against other previously launched multiple sclerosis (MS) agents, in particular Gilenya and Aubagio, the first two oral MS therapies to market.
